Showing results (321-330 of 336) with videos related to

Sort By:
Pageof 34
Journal of Thrombosis and Haemostasis : JTH|November 25, 2021
Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension studyHeng Mei, Xiaofan Liu, Yan Li, et al.
Journal of Hematology & Oncology|February 26, 2021
A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopeniaHeng Mei, Xiaofan Liu, Yan Li, et al.
Cancer Biology & Medicine|March 2, 2023
2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphomaPing Li, Yang Liu, Yun Liang, et al.
Frontiers in Oncology|November 22, 2021
A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in ChinaWeiping Liu, Donglu Zhao, Ting Liu, et al.
Innovation (Cambridge (Mass.))|May 14, 2023
Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: A randomized phase III studyHuijuan Zhong, Shu Cheng, Xi Zhang, et al.
American Journal of Hematology|January 22, 2022
Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysisXiao-Dong Mo, Shen-Da Hong, Yan-Li Zhao, et al.
Platelets|July 3, 2020
Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of agePeng Zhao, Ming Hou, Yi Liu, et al.
The New England Journal of Medicine|December 9, 2025
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple MyelomaLuciano J Costa, Nizar J Bahlis, Aurore Perrot, et al.
Bone Marrow Transplantation|November 26, 2024
A multifactorial risk scoring system for the prediction of early relapse in CMML patients with allo-HSCT: a nationwide representative multicenter studyJian-Ying Zhou, Yu-Xiu Chen, Hai-Long Yuan, et al.
Haematologica|April 10, 2025
Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized studyHuijuan Zhong, Shu Cheng, Jie Xiong, et al.
Pageof 34